Clinical Trials
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
Latest Clinical Trial Results
SAN FRANCISCO, July 03, 2008 /PRNewswire-FirstCall/ --
Medivation, Inc. today announced that it will hold a teleconference
at 5:00 p.m. EDT on Monday, July 7, to discuss top-line results
from its randomized, double-blind, placebo-controlled Phase...
MUNICH, Germany, July 3,2008- Munich-based biopharmaceutical
company WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange /
Prime Standard) today announced that it has successfully completed
patient recruitment in the Phase III ARISER trial with...
HOUSTON, July 2, 2008 – Thyroid cancer that has
spread to distant sites has a poor prognosis, but an experimental
drug that inhibits tumor blood vessel formation can slow disease
progression in some patients, a research team led by...
HAMBURG, Germany, July 3, 2008 -Evotec AG (Frankfurt Stock
Exchange: EVT; NASDAQ: EVTC) announced today top-line results of a
double-blind, 4-week Phase Ib study with EVT 101, an orally active
NR2B-subtype selective antagonist of NMDA receptors...
BEDFORD, Mass.--(BUSINESS WIRE)--Jul 3, 2008 - Resolvyx
Pharmaceuticals, Inc., the leading resolvin therapeutics company,
today announced that a research team led by a Resolvyx scientific
advisor and a company co-founder has demonstrated that the...
CAMBRIDGE, England, July 3, 2008-Intercytex Group plc (LSE: ICX)
the leading developer of regenerative medicine products to restore
skin and hair, today announces that positive 6 month follow-up data
from two Phase II trials of VAVELTA, its cell...
BOSTON--(BUSINESS WIRE)--Jul 2, 2008 - A new study published in
Endocrine Practice found that a substantial percentage of patients
with nodules, or growths, in their adrenal glands were not being
properly evaluated by physicians.
Adrenal glands are...
FREMONT, Calif.--(BUSINESS WIRE)--Jul 2, 2008 - ARYx Therapeutics,
Inc., (NASDAQ:ARYX), a biopharmaceutical company, today announced
the results of an important cardiac safety study on its prokinetic
agent, ATI-7505. The overall results of a...
Parathyroid Hormone, Calcium, and Phosphorous Levels are
Important
WASHINGTON - June 30, 2008- Consistently maintaining
certain blood levels of markers of bone metabolism and disease can
prolong the lives of patients on hemodialysis, according...
- Pre-Specified Primary Efficacy Endpoint Met in Stage 1 of
Two-Stage Study -
TUSTIN, Calif., July 2, 2008 /PRNewswire-FirstCall/ -- Peregrine
Pharmaceuticals, Inc. today reported that its lead product
candidate bavituximab achieved the...
SAN DIEGO--(BUSINESS WIRE)--Jul 2, 2008 - MicroIslet Inc. (OTCBB:
MIIS, http://www.microislet.com), a biotechnology company engaged
in the development and commercialization of cell therapies for
diabetes, is pleased to report recent safety and...
NEW YORK, July 1, 2008--In June 2008, the U.S. FDA updated the
ATRIPLA package insert (PI) with additional safety and efficacy
data, showing ATRIPLA's durability of response over three
years.
The updated ATRIPLA PI is based on 144-week data from...
- Study also points to potential of pre-treatment R2 levels as a
possible predictor of clinical activity -
TORONTO, July 2, 2008 /PRNewswire-FirstCall/ - Lorus
Therapeutics Inc. ("Lorus" or the "Corporation"), a
biopharmaceutical company...
PARIS and GAITHERSBURG, Maryland, July 02, 2008
/PRNewswire-FirstCall/ -- ExonHit Therapeutics , a drug and
diagnostic company, today announced its presence at the
International Conference on Alzheimer's Disease (ICAD 2008) taking
place in Chicago...
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Jul 2, 2008 - Titan
Pharmaceuticals, Inc. (AMEX:TTP) today announced initial analyses
show that Spheramine(R) did not meet the Phase IIb clinical study's
primary or key secondary endpoints, with no significant...
CHICAGO, July 1, 2008—In industrialized countries, persons
infected sexually with HIV now appear to experience mortality rates
similar to those of the general population in the first 5 years
following infection, though a higher risk of death...
PHILADELPHIA, July 01, 2008 /PRNewswire-USNewswire/ --
Researchers have found that a gene region known to play a role in
some varieties of adult rheumatoid arthritis is also present in all
types of childhood arthritis. The researchers say the...
Submission of Five-Day Dosing Regimen sNDA Targeted for Fiscal
Year-end 2008
WOODCLIFF LAKE, N.J., July 01, 2008, 2008 /PRNewswire/ -- Eisai
Corporation of North America today announced the preliminary
efficacy data from a trial initiated in 2002...
Findings in rats show promise for 'buying time' in victims of
lethal hemorrhage
SEATTLE, July 01, 2008 /PRNewswire/ -- For the first time,
researchers have demonstrated that the administration of minute
amounts of inhaled or intravenous hydrogen...
MEMPHIS, Tenn.--(BUSINESS WIRE)--Jul 1, 2008 - arGentis
Pharmaceuticals, LLC announced today that it has filed a patent
application for Nucleic Acid Sequences highly associated with the
inability of oral immune tolerance to be induced in some...
More...Clinical Trial Results Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec
